摘要
目的:探讨氯比格雷对非ST段抬高的急性冠脉综合征的临床疗效及安全性。方法:将133例患者按入选顺序随机分为常规治疗组和氯比格雷组。常规治疗组接受常规治疗,氯比格雷组在常规治疗组的基础上加氯比格雷。结果:与对照组相比,治疗组患者心电图各导联ST段压低情况明显改善,明显降低心力衰竭的发生率及心血管原因死亡。治疗前后凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)及血小板计数(PLT)无统计学差异。结论:氯比格雷对非ST段抬高的急性冠脉综合征有效,且不增加副作用。
Objective：To study the efficacy and safety of clopidogred in non-ST segment elevating acute coronary syndrome （NSTEACS）based on routine therapies.Methods： 133 cases of NSTEACS were randomly divided into two groups： General group was 64 cases with routine therapy.Clopidogrel group was 69 cases who were given with clopidogrel besides routine therapy.Resilts：Compared with the General group ,the effects of the drags on electrocardiogram ST segment was improved and there was lower incidence of heart failure and death in the clopidogrel group.Plasma PT.AFIT.and PLT of pretreatment and posttreatment had no significant difference.Conclusion：Clopidogrel in treatment of non-ST segment elevating acute coronary syndrome has shown effectiveness and safety.There is no significanc ant difference inside reaction be- tween the two groups.
出处
《中国医药导报》
CAS
2007年第10Z期32-33,共2页
China Medical Herald
